NCT00922766 - Effectiveness And Safety Of Dalteparin In Patients With Acute Coronary Syndromes Without ST Elevations In Clinical Practice | Biotech Hunter

Enrollment

618

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Dalteparin

Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).

Trial Locations (24)

3

Pfizer Investigational Site, Nashik

125005

Pfizer Investigational Site, Hisar

302019

Pfizer Investigational Site, Jaipur

334003

Pfizer Investigational Site, Bikaner

395004

Pfizer Investigational Site, Surat

421501

Pfizer Investigational Site, Ambernath (E)

440012

Pfizer Investigational Site, Nagpur

440017

Pfizer Investigational Site, Nagpur

440033

Pfizer Investigational Site, Nagpur

562114

Pfizer Investigational Site, Bangalore

380 051

Pfizer Investigational Site, Ahmedabad

125 001

Pfizer Investigational Site, Hisar

575 018

Pfizer Investigational Site, Manglore

570 020

Pfizer Investigational Site, Mysore

440 001

Pfizer Investigational Site, Nagpur

440 010

Pfizer Investigational Site, Nagpur

422 002

Pfizer Investigational Site, Nashik

Pfizer Investigational Site, Nashik Road

422 009

Pfizer Investigational Site, Nashik

422 101

Pfizer Investigational Site, Nashik Road

Unknown

Pfizer Investigational Site, Thāne

302 012

Pfizer Investigational Site, Jaipur

600 035

Pfizer Investigational Site, Chennai

700 019

Pfizer Investigational Site, Kolkata